OncoMatch/Clinical Trials/NCT07106814
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Is NCT07106814 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Metabolically Armed TIL cells for advanced solid tumors.
Treatment: Metabolically Armed TIL cells — A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IV, PERSISTENT, III, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE C, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B UNSUITABLE FOR LOCAL THERAPY OR PROGRESSED AFTER LOCAL THERAPY (FIGO 2018 (cervical), BCLC (liver))
Excluded: Stage EARLY-STAGE CERVICAL CANCER (UNLESS CRITERIA ARE RELAXED IN FUTURE)
Stage Ⅳ cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO 2018) staging criteria; BCLC Stage C or Stage B unsuitable for local therapy or progressed after local therapy; advanced solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥1x10^9/L; PLT ≥80 × 10^9/L; Hb ≥90.0 g/L; no transfusions, platelet infusions, or growth factor support (except recombinant erythropoietin) within 7 days prior to enrollment
Kidney function
Estimated creatinine clearance ≥40 mL/min (Cockcroft-Gault formula)
Liver function
ALT ≤3 × ULN; AST ≤3 × ULN; TBIL ≤2 mg/dL (≤3 mg/dL for Gilbert-Meulengracht syndrome); AST and ALT ≤5 × ULN (subjects with liver metastasis); Child-Pugh score ≤7
Cardiac function
LVEF ≥45% by echocardiography or MUGA scan, with hemodynamic stability
Adequate organ function: Hematological (no transfusions, platelet infusions, or growth factor support [except recombinant erythropoietin] within 7 days prior to enrollment): ANC≥1x10^9/L; PLT ≥80 × 10^9/L; Hb ≥90.0 g/L; Blood chemistry: Estimated creatinine clearance ≥40 mL/min (Cockcroft-Gault formula); ALT ≤3 × ULN; AST ≤3 × ULN; TBIL ≤2 mg/dL (≤3 mg/dL for Gilbert-Meulengracht syndrome); AST and ALT ≤5 × ULN (subjects with liver metastasis); Child-Pugh score ≤7; Adequate pulmonary reserve defined as ≤Grade 1 dyspnea and oxygen saturation >91% on room air; LVEF ≥45% by echocardiography or MUGA scan, with hemodynamic stability
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07106814 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV or PERSISTENT or III or BARCELONA CLINIC LIVER CANCER (BCLC) STAGE C or BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B UNSUITABLE FOR LOCAL THERAPY OR PROGRESSED AFTER LOCAL THERAPY is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify